Page last updated: 2024-12-07
tetramethrin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tetramethrin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 83975 |
CHEMBL ID | 1788386 |
CHEBI ID | 39397 |
SCHEMBL ID | 27009 |
MeSH ID | M0054117 |
Synonyms (118)
Synonym |
---|
insectol |
bioneopynamin |
hsdb 6738 |
tetrametrina [spanish] |
(1-cyclohexene-1,2-dicarboximido)methyl-2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylate |
neopynamin forte |
epa pesticide chemical code 069003 |
tetramethrinum [latin] |
tetramethrine [iso-french] |
tetramethrin,racemic |
(1,3,4,5,6,7-hexahydro-1,3-dioxo-2h-isoindol-2-yl) methyl 2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylate |
(1-cyclohexane-1,2-dicarboximido)methyl chrysanthemumate |
cyclohex-1-ene-1,2-dicarboximidomethyl (+-)-cis-trans-chrysanthemate |
ai3-27339 |
2,3,4,5-tetrahydrophthalimidomethylchrysanthemate |
1-cyclohexene-1,2-dicarboximidomethyl-2,2-dimethyl-3-(2-methylpropenyl)cyclopropane carboxylate |
ccris 3284 |
tetramethrine |
fmc-9260 |
n-(chrysanthemoxymethyl)-1-cyclohexene-1,2-dicarboximide |
ent 27339 |
sumitomo sp-1103 |
1-(cyclohexene-1,2-dicarboximido)methyl 2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylate |
einecs 231-711-6 |
3,4,5,6-tetrahydrophthalimidomethyl (+-)-cis-trans-chrysanthemate |
2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylic acid (1,3,4,5,6,7-hexahydro-1,3-dioxo-2h-isoindol-2-yl)methyl ester |
tetramethrine [french] |
sp 1103 forte |
caswell no. 844 |
2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylic acid ester withn-(hydroxymethyl)-1-cyclohexene-1,2-dicarboximide |
n-(3,4,5,6-tetrahydrophthalimido)-methyl dl-cis-trans-chrysanthemate |
n-(3,4,5,6-tetrahydrophthalimide)methyl-cis,trans-chrysanthemate |
sp-1103 |
d-phthalthrin |
nia-9260 |
tetramethrin [inn] |
py-kill |
2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylic acid, ester with n-(hydroxymethyl)-1-cyclohexene-1,2-dicarboximide or 1-cyclohexene-1,2-dicarboximidomethyl 2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylate |
tetralate |
niagara nia-9260 |
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propenyl)-, (1,3,4,5,6,7-hexahydro-1,3-dioxo-2h-isoindol-2-yl)methyl ester |
d-tetramethrin |
cyclohex-1-ene-1,2-dicarboximidomethyl (1rs)-cis,trans-2,2-dimethyl-3-(2-methyl-prop-1-enyl)cyclopropane carboxylate |
3,4,5,6-tetrahydro-phthalimidomethylester der dl-cis-trans-chrysanthemumsaeure [german] |
weo-pynamin |
3,4,5,6-tetrahydrophthalimidomethyl cis and trans dl chrysanthemummonocarboxylic acid |
cyclohexene-1-dicarboximidomethylchrysanthemate |
neopinamine |
D07368 |
tetramethrin (inn) |
tetramethrin, analytical standard |
(1,3-dioxo-1,3,4,5,6,7-hexahydro-2h-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate |
phthalthrin |
CHEBI:39397 , |
neopinamin |
7696-12-0 |
neo-pynamin |
tetramethrin |
MAYBRIDGE1_001977 |
SR-01000641045-1 |
NCGC00168352-01 |
OPREA1_283726 |
HMS547B19 |
(1,3-dioxo-4,5,6,7-tetrahydroisoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate |
C18373 |
dtxsid6032649 , |
tox21_301017 |
tox21_112623 |
NCGC00254919-01 |
cas-7696-12-0 |
dtxcid4012649 |
MLS004712089 |
smr001825216 |
66525-27-7 |
AKOS015965024 |
CCG-51764 |
tetramethrinum |
unii-z72930q46k |
3,4,5,6-tetrahydro-phthalimidomethylester der dl-cis-trans-chrysanthemumsaeure |
tetramethrin [inn:ansi:bsi:iso] |
z72930q46k , |
tetrametrina |
CHEMBL1788386 |
SCHEMBL27009 |
tox21_112623_1 |
NCGC00168352-02 |
KS-5080 |
tetramethrin [mart.] |
2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylic acid, ester with n-(hydroxymethyl)-1-cyclohexene-1,2-dicarboximide |
tetramethrin [inci] |
tetramethrin [mi] |
1-cyclohexene-1,2-dicarboximidomethyl 2,2-dimethyl-3-(2-methylpropenyl)cyclopropanecarboxylate |
tetramethrin [iso] |
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propen-1-yl)-, (1,3,4,5,6,7-hexahydro-1,3-dioxo-2h-isoindol-2-yl)methyl ester |
tetramethrin [hsdb] |
tetramethrin [who-dd] |
killgerm py-kill w |
(1-cyclohexene-1,2-dicarboximido)methyl chrysanthemumate |
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methylpropenyl)-, ester with n-(hydroxymethyl)-1-cyclohexene-1,2-dicarboximide |
CXBMCYHAMVGWJQ-UHFFFAOYSA-N |
(1-cyclohexene-1,2-dicarboximido)methyl chrysanthemate |
(1,3-dioxo-1,3,4,5,6,7-hexahydro-2h-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropanecarboxylate # |
tetramethrin racemic |
W-104333 |
3,4,5,6-tetrahydrophthalimidomethyl (+/-)-cis-trans-chrysanthemate |
tetramethrin, pestanal(r), analytical standard |
tetramethrin; phthalthrin |
tetramethrin 10 microg/ml in cyclohexane |
(1,3-dioxo-4,5,6,7-tetrahydro-1h-isoindol-2(3h)-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate |
cyclopropanecarboxylic acid,2,2-dimethyl-3-(2-methyl-1-propenyl)-,(1,3,4,5,6,7-hexahydro-1,3-dioxo-2h-isoindol-2-yl)methyl ester |
Q3234577 |
DB13752 |
mfcd00084635 |
CS-W020889 |
AMY3567 |
E78274 |
HY-W040149 |
(1,3,4,5,6,7-hexahydro-1,3-dioxo-2h-isoindol-2-yl)methyl(1r-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate |
Research Excerpts
Overview
Tetramethrin is a widely applied type I chiral pyrethroid insecticide. It has been reported to exert estrogen-antagonistic effects selectively on female rats.
Excerpt | Reference | Relevance |
---|---|---|
"Tetramethrin is a pyrethroid insecticide that is commonly used worldwide. " | ( Novel Mechanism and Kinetics of Tetramethrin Degradation Using an Indigenous Bhatt, P; Chen, S; Guo, Y; Huang, Y; Lin, Z; Pang, S; Yu, H; Zhang, G; Zhou, T, 2021) | 2.35 |
"Tetramethrin (Tm) is a commonly used pesticide that has been reported to exert estrogen-antagonistic effects selectively on female rats. " | ( Lobaric acid prevents the adverse effects of tetramethrin on the estrous cycle of female albino Wistar rats. Annam, SSP; Nguyen, HT; Okello, E; Polimati, H; Tatipamula, VB; Thai, QM; Vu, TY, 2022) | 2.42 |
"Tetramethrin is a widely applied type I chiral pyrethroid insecticide that exists as a mixture of four isomers. " | ( Systematic Stereoselectivity Evaluations of Tetramethrin Enantiomers: Stereoselective Cytotoxicity, Metabolism, and Environmental Fate in Earthworms, Soils, Vegetables, and Fruits. Di, X; Guo, G; Ma, S; Wang, L; Yu, J, 2023) | 2.61 |
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" As a result, the findings showed that although pyrethroids are considered to be of low acute toxicity, they become more toxic when combined with piperonyl butoxide or tetramethrin in certain doses." | ( Repeated-dose 14-day dermal toxicity of different combinations of some synthetic pyrethroid insecticides, piperonyl butoxide, and tetramethrin in rats. Aksoy, A; Atmaca, E; Cenesiz, M; Das, YK; Gulbahar, MY; Guvenc, D; Yarim, GF; Yavuz, O, 2010) | 0.76 |
" Strikingly, in (Tm + La)-treated rats, all the observed adverse effects of Tm on the hormonal parameters, cell morphology, and the length of each phase of estrous cycle were significantly diminished in a dose-dependent manner." | ( Lobaric acid prevents the adverse effects of tetramethrin on the estrous cycle of female albino Wistar rats. Annam, SSP; Nguyen, HT; Okello, E; Polimati, H; Tatipamula, VB; Thai, QM; Vu, TY, 2022) | 0.98 |
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" The experimental data for the time course of the concentration of tetramethrin isomers in plasma fit a pharmacokinetic two-compartmental open model." | ( The pharmacokinetics and metabolism of (1R, cis)- and (1R, trans)-tetramethrin in rats. Dauterman, WC; Silver, IS, 1989) | 0.75 |
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
"Dispersive liquid microextraction (DLME) combined with dispersive µ-solid phase extraction (D-µ-SPE) has been developed as a new approach for the extraction of four pyrethroids (tetramethrin, fenpropathrin, deltamethrin and permethrin) prior to the analysis by high performance liquid chromatography (HPLC) with UV detection." | ( Two-step microextraction combined with high performance liquid chromatographic analysis of pyrethroids in water and vegetable samples. Mukdasai, S; Srijaranai, S; Thomas, C, 2014) | 0.59 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" From the dose-response relation the dissociation constant for Ca block at 0 mV was estimated to be 32." | ( Voltage-dependent calcium block of normal and tetramethrin-modified single sodium channels. Narahashi, T; Yamamoto, D; Yeh, JZ, 1984) | 0.53 |
" 14C-recoveries (expressed as percentages relative to the dosed 14C) in faeces and urine were 38-58 and 42-58% respectively in rat administrated trans-[alcohol-14C]tetramethrin, and in faeces and urine were 66-91 and 9-31% respectively in rat administered cis-[alcohol-14C]tetramethrin." | ( Metabolism of tetramethrin isomers in rat: II. Identification and quantitation of metabolites. Isobe, N; Kaneko, H; Mori, M; Nakatsuka, I; Shiba, K; Tomigahara, Y; Yamada, H, 1994) | 0.84 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
Role | Description |
---|---|
pyrethroid ester insecticide | null |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
Class | Description |
---|---|
phthalimide insecticide | |
maleimides | Compounds containing a cyclic dicarboximide skeleton in which the two carboacyl groups on nitrogen together with the nitrogen itself form a 1H-pyrrole-2,5-dione structure. |
cyclopropanecarboxylate ester | A carboxylic ester resulting from the formal condensation of the hydroxy group of an alcohol or phenol with the carboxy group of cyclopropanecarboxylic acid or its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (32)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 47.0294 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 17.2463 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
USP1 protein, partial | Homo sapiens (human) | Potency | 44.6684 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
SMAD family member 3 | Homo sapiens (human) | Potency | 17.2463 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
AR protein | Homo sapiens (human) | Potency | 16.8596 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 33.4915 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 35.8608 | 0.0010 | 22.6508 | 76.6163 | AID1224839 |
cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 28.1190 | 0.0123 | 7.9835 | 43.2770 | AID1346984; AID1645841 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 54.9410 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 11.4575 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 8.7544 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 43.0433 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259401; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 39.7212 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID1346985 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 26.4028 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743080; AID743091 |
G | Vesicular stomatitis virus | Potency | 8.7090 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2D6 | Homo sapiens (human) | Potency | 6.9178 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 18.2118 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 0.0022 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 11.5109 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 64.8601 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 19.9526 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 47.6398 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 47.5668 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 46.6793 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 40.5334 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 24.3365 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Interferon beta | Homo sapiens (human) | Potency | 8.7090 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 8.7090 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 32.2044 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 24.3365 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 8.7090 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 8.7090 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (168)
Molecular Functions (50)
Ceullar Components (36)
Bioassays (35)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (96)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 28 (29.17) | 18.7374 |
1990's | 19 (19.79) | 18.2507 |
2000's | 12 (12.50) | 29.6817 |
2010's | 22 (22.92) | 24.3611 |
2020's | 15 (15.63) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 33.78
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.78) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (2.04%) | 6.00% |
Case Studies | 3 (3.06%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 93 (94.90%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |